Article Text
Editorial
Clinical outcomes of potent antiplatelets compared with clopidogrel in ST elevation myocardial infarction
Statistics from Altmetric.com
Footnotes
Contributors SSN is the sole author of the editorial.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SSN has received speaker honoraria from AstraZeneca and research funding from AstraZeneca.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.